In vivo, NEK6 knockdown significantly enhances sensitivity to DOX in ovarian cancer xenografts derived from SKOV3/DDP cells and reduces tumor volume (Figs. 3G, H and S8D). This evidence concerns the gene NEK6 and ovarian carcinoma.